Chimerix

Pipeline

Chimerix has established a pipeline of therapeutics addressing life-threatening viral diseases.  Our lead compound, CMX001, is currently being developed to treat dsDNA viruses – potentially deadly diseases for immunocompromised patients.  As a potential broad-spectrum antiviral agent with enhanced in vitro potency, CMX001 is also being studied as a promising biodefense countermeasure for use in the event of a smallpox outbreak.  A second compound, CMX157, is being advanced to treat human immunodeficiency virus (HIV).  In addition, we have identified highly active compounds against hepatitis C and influenza and are screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis.

Scientific Foundation

Our pipeline is fueled by two proprietary sources derived from the innovations of renowned antiviral scientists. Our Lipid-Antiviral-Conjugate Technology was originally developed by Karl Hostetler, M.D., Professor of Medicines at the University of California, San Diego and a leading expert in the field of infectious disease. The Conjugate Technology is used to modify a drug molecule so that it mimics a naturally occurring phospholipid. Read More


Licensing Opportunities

Chimerix has amassed an unusual breadth of assets with considerable potential in antiviral innovation, including our Lipid-Antiviral-Conjugate Technology and the Chimerix Chemical Library. The combination of our team’s internal antiviral product expertise with a number of internally-generated leads against several important viruses allows us the flexibility to pursue out-licensing or co-development partners for our emergent antiviral medicines. Read More